H. Ekberg, H. Tedesco-silva, A. Demirbas, S. Vitko, B. Nashan et al., Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation, New England Journal of Medicine, vol.357, issue.25, pp.2562-2575, 2007.
DOI : 10.1056/NEJMoa067411

R. Margreiter, Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study, The Lancet, vol.359, issue.9308, pp.741-746, 2002.
DOI : 10.1016/S0140-6736(02)07875-3

P. Wallemacq, V. Armstrong, M. Brunet, V. Haufroid, D. Holt et al., Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference, Therapeutic Drug Monitoring, vol.31, issue.2, pp.139-152, 2009.
DOI : 10.1097/FTD.0b013e318198d092

L. Elens, D. Hesselink, R. Van-schaik, and T. Van-gelder, Pharmacogenetics in Kidney Transplantation, Molecular Diagnosis & Therapy, vol.17, issue.4, pp.331-345, 2012.
DOI : 10.1007/s40291-012-0012-5

E. Thervet, D. Anglicheau, B. King, M. Schlageter, B. Cassinat et al., Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12, Transplantation, vol.76, issue.8, pp.1233-1235, 2003.
DOI : 10.1097/01.TP.0000090753.99170.89

L. Elens, R. Bouamar, D. Hesselink, V. Haufroid, I. Van-der-heiden et al., A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients, Clinical Chemistry, vol.57, issue.11, pp.1574-1583, 2011.
DOI : 10.1373/clinchem.2011.165613

P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem et al., Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nature Genetics, vol.27, issue.4, pp.383-391, 2001.
DOI : 10.1038/86882

L. Elens, R. Bouamar, N. Shuker, D. Hesselink, T. Van-gelder et al., Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks, British Journal of Clinical Pharmacology, vol.7, issue.Suppl. 1, pp.715-728, 2014.
DOI : 10.1111/bcp.12253

I. Macphee, S. Fredericks, T. Tai, P. Syrris, N. Carter et al., The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation, American Journal of Transplantation, vol.72, issue.5, pp.914-919, 2004.
DOI : 10.1177/0091270003043006001

N. Shuker, R. Bouamar, R. Van-schaik, M. Clahsen-van-groningen, J. Damman et al., A Randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with bodyweight-based tacrolimus dosing after living donor kidney transplantation, Am J Transplant, 2015.

S. Terrazzino, M. Quaglia, P. Stratta, P. Canonico, and A. Genazzani, The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients, Pharmacogenetics and Genomics, vol.22, issue.8, pp.642-645, 2012.
DOI : 10.1097/FPC.0b013e3283557c74

E. Thervet, M. Loriot, S. Barbier, M. Buchler, M. Ficheux et al., Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing, Clinical Pharmacology & Therapeutics, vol.87, issue.6, pp.721-726, 2010.
DOI : 10.1097/00007890-200212150-00002

H. Ekberg, R. Mamelok, T. Pearson, F. Vincenti, H. Tedesco-silva et al., The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony Study, Transplantation, vol.87, issue.9, pp.1360-1366, 2009.
DOI : 10.1097/TP.0b013e3181a23cb2

V. Gijsen, P. Madadi, M. Dube, D. Hesselink, G. Koren et al., Tacrolimusinduced nephrotoxicity and genetic variability: a review, Ann Transplant, vol.17, issue.2, pp.111-121, 2012.

E. Storset, A. Asberg, M. Skauby, M. Neely, S. Bergan et al., Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients???A Prospective, Randomized Study, Transplantation, vol.99, issue.10, pp.2158-2166, 2015.
DOI : 10.1097/TP.0000000000000708

J. Bloch, M. Hazzan, C. Van-der-hauwaert, D. Buob, G. Savary et al., genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients, Pharmacogenomics, vol.15, issue.16, pp.2011-2024, 2014.
DOI : 10.2217/pgs.14.146

J. Moore, A. Mcknight, B. Dohler, M. Simmonds, A. Courtney et al., Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure, Journal of the American Society of Nephrology, vol.23, issue.11, pp.1891-1899, 2012.
DOI : 10.1681/ASN.2012030260

A. Lievre, J. Bachet, L. Corre, D. Boige, V. Landi et al., KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer, Cancer Research, vol.66, issue.8, pp.3992-3995, 2006.
DOI : 10.1158/0008-5472.CAN-06-0191

J. Wu, J. Edberg, P. Redecha, V. Bansal, P. Guyre et al., A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease., Journal of Clinical Investigation, vol.100, issue.5, pp.1059-1070, 1997.
DOI : 10.1172/JCI119616